Drawing for Serial No. 79200117

USPTO serial 79200117

Serial No. 79200117

Reviewed by CopyMark Law Group

Reg. 5494415Status 709
Filing date
Status date
Registration date
Jun 19, 2018
Examiner
DUBIN, DAVID I
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79200117?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Martin J. Beran

MARTIN J. BERAN OSTROLENK FABER LLP1180 AVENUE OF THE AMERICAS7TH FLOORNEW YORK, NY 10036UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biochemical and biological products, substances and preparations, namely, reagents, antibodies, proteins, nucleic acids, fusion proteins, stem cells, and gene therapy preparations for industrial, scientific and research purposesSECTION 71 - CANCELLED—
005Pharmaceutical preparations for the treatment of diseases and disorders of the alimentary tract and metabolism, blood and blood forming organs, the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system, dermatological, hormonal, infectious, viral, immunological and oncological diseases and disorders; preparations for health care in the nature of medical preparations for the treatment of diseases and disorders of the alimentary tract and metabolism, and blood and blood forming organs, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system, dermatological, hormonal, infectious, viral, immunological and oncological diseases and disorders; bacteriological preparations for medical and veterinary use; biological preparations for medical and for veterinary purposes for the treatment of diseases and disorders of the alimentary tract and metabolism, and blood and blood forming organs, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system, dermatological, hormonal, infectious, viral, immunological and oncological diseases and disorders; biochemical preparations for medical and veterinary purposes for the treatment of diseases and disorders of the alimentary tract and metabolism, blood and blood forming organs, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system and for the treatment of dermatological, hormonal, infectious, viral and oncological diseases and disorders; Chemical preparations for medical purposes for the treatment of diseases and disorders of the alimentary tract and metabolism, and blood and blood forming organs, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system, dermatological, hormonal, infectious, viral, immunological and oncological diseases and disorders; ferments for pharmaceutical purposes; vaccines; culture media for cultivating microorganism cells for biotechnological research and manufacturing; plasters and dressings for medical purposesSECTION 71 - CANCELLED—
042Scientific and technological services, namely, scientific research, analysis and testing of active substances, medicine and treatments in the fields of biotechnology, development of active medical substances, medicines, pharmaceuticals, and biotechnology; research and development of new products in the field of biotechnology; technical and scientific consultancy in the field of biotechnology; conducting clinical trials for others in the field of pharmaceutical productsSECTION 71 - CANCELLED—
044Medical and veterinary consulting; providing medical and veterinary information via the Internet; all the aforementioned consultations and services also provided through a database; providing medical information via the InternetSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 5, 2026INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Feb 14, 2026INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Feb 14, 2026INPCINVALIDATION PROCESSED—
Sep 10, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 3, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jan 3, 2025C71TCANCELLED SECTION 71—
Jun 19, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 12, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 21, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 21, 2018FIMPFINAL DISPOSITION PROCESSED—
Sep 19, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 29, 2018OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jun 19, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 14, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jun 14, 2018OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 3, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 3, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 30, 2018GPNXNOTIFICATION PROCESSED BY IB—
Mar 14, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 14, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 14, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 1, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 27, 2018ALIEASSIGNED TO LIE—
Feb 21, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 21, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Feb 21, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 21, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 21, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 15, 2018ZZAXPREVIOUS ALLOWANCE WITHDRAWN-TIMELY AAU—
Jan 30, 2018PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Jan 9, 2018EXPTEXPARTE APPEAL TERMINATED—
Jan 9, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 5, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Jan 5, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 5, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 5, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 22, 2017ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Dec 22, 2017EXPIEX PARTE APPEAL-INSTITUTED—
Dec 22, 2017JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Dec 22, 2017EXAFEXPARTE APPEAL RECEIVED AT TTAB—
Jun 22, 2017GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 22, 2017GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 22, 2017CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 25, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 25, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 25, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 22, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 18, 2017RFNTREFUSAL PROCESSED BY IB—
Jan 25, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 25, 2017RFRRREFUSAL PROCESSED BY MPU—
Jan 20, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 19, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 19, 2017RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Jan 17, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 14, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 13, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2017DOCKASSIGNED TO EXAMINER—
Jan 13, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 12, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance